Zhitong Finance App News, Columbotai Bio-B (06990.HK) announced that the new drug application (NDA) (NDA) (previously known as A166), an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) (previously known as A166) has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for adult treatment of patients with HER2-positive non-metastatic or her2 mastectomies.

Zhitongcaijing · 01/07 11:09
Zhitong Finance App News, Columbotai Bio-B (06990.HK) announced that the new drug application (NDA) (NDA) (previously known as A166), an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) (previously known as A166) has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for adult treatment of patients with HER2-positive non-metastatic or her2 mastectomies.